Importer of Controlled Substances, Notice of Application, Hospira, 75670 [2012-30782]

Download as PDF 75670 Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices Portland, OR; VicTrack, Docklands, AUSTRALIA; VIP Operator, Skopje, MACEDONIA; Virtus IT Limited, London, UNITED KINGDOM; VISITEK, Jakarta Selatan, INDONESIA; Vitria Technology, Inc., Sunnyvale, CA; Vonage, Holmdel, NJ; Wataniya Telecom Kuwait, Plot 1A, Sharq Area, KUWAIT; Wind Telecomunicazioni SpA, Roma, ITALY; WiTech, Cascina, ITALY; Xelas software, Marina del Rey, CA; XTRAC, LLC, Boston, MA; Yyield Group BV, Bennebroek, NETHERLANDS; Zain, Safat, KUWAIT; ZAO ‘‘Glasnet’’, Korolev, RUSSIA; Zenoss, Annapolis, MD and Zenulta Limited, Swindon, UNITED KINGDOM. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and The Forum intends to file additional written notifications disclosing all changes in membership. On October 21, 1988, The Forum filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on December 8, 1988 (53 FR 49615). The last notification was filed with the Department on August 22, 2011. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on November 18, 2011 (76 FR 71602). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 22, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: December 14, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–30782 Filed 12–20–12; 8:45 am] BILLING CODE 4410–09–P [FR Doc. 2012–30724 Filed 12–20–12; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration; Fisher Clinical Services,Inc. mstockstill on DSK4VPTVN1PROD with Importer of Controlled Substances, Notice of Application, Hospira Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on September 20, 2012, Hospira, 1776 North Centennial Drive, McPherson, Kansas 67460–1247, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of Remifentanil (9739), a basic class of controlled substance listed in schedule II. The company plans to import Remifentanil for use in dosage form manufacturing. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture VerDate Mar<15>2010 18:28 Dec 20, 2012 Jkt 229001 By Notice dated September 20, 2012, and published in the Federal Register on October 2, 2012, 77 FR 60143, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of noroxymorphone (9668), a basic class of controlled substance in schedule II. The company plans to import the listed substances for analytical research and clinical trials. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Fisher Clinical Services, Inc., to import PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Fisher Clinical Services, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: December 14, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–30784 Filed 12–20–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Registration, AMRI Rensselaer, Inc. By Notice dated July 30, 2012, and published in the Federal Register on August 7, 2012, 77 FR 47114, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Pentobarbital (2270) ..................... 4-Anilino-N-phenethyl-4-piperidine (8333). Meperidine (9230) ........................ Fentanyl (9801) ............................ Schedule I I II II II II II II II The company plans to manufacture bulk controlled substances for use in product development and for distribution to its customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance E:\FR\FM\21DEN1.SGM 21DEN1

Agencies

[Federal Register Volume 77, Number 246 (Friday, December 21, 2012)]
[Notices]
[Page 75670]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-30782]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances, Notice of Application, Hospira

    Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this 
is notice that on September 20, 2012, Hospira, 1776 North Centennial 
Drive, McPherson, Kansas 67460-1247, made application by renewal to the 
Drug Enforcement Administration (DEA) for registration as an importer 
of Remifentanil (9739), a basic class of controlled substance listed in 
schedule II.
    The company plans to import Remifentanil for use in dosage form 
manufacturing.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43, and in 
such form as prescribed by 21 CFR 1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than January 22, 2013.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substance in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-30782 Filed 12-20-12; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.